An Indole-2-Carboxamide Derivative, LG4, Alleviates Diabetic Kidney Disease Through Inhibiting MAPK-Mediated Inflammatory Responses

References

• Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361–377. doi:10.1038/s41581-018-0001-y
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64(4):510–533. doi:10.1053/j.ajkd.2014.08.001
   PubMed Web of Science ®Google Scholar
• Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci. 2013;124(3):139–152. doi:10.1042/CS20120198
   PubMed Web of Science ®Google Scholar
• Hasslacher C. Diabetic nephropathy: structural-functional relationships. Contrib Nephrol. 1989;73:24–28.
   PubMedGoogle Scholar
• Lehman R, Gerber PA. End-stage nephropathy in type 1-diabetes mellitus - kidney transplantation alone or combined with islet or pancreas transplantation? Ther Umsch. 2011;68(12):699–706. doi:10.1024/0040-5930/a000233
   PubMedGoogle Scholar
• Grande MT, Pérez-Barriocanal F, López-Novoa JM. Role of inflammation in túbulo-interstitial damage associated to obstructive nephropathy. J Inflamm. 2010;7(1):19. doi:10.1186/1476-9255-7-19
   Google Scholar
• Schelling JR. Tubular atrophy in the pathogenesis of chronic kidney disease progression. Pediatr Nephrol. 2016;31(5):693–706. doi:10.1007/s00467-015-3169-4
   PubMed Web of Science ®Google Scholar
• Wee YM, Lee HW, Choi MY, et al. A composite of urinary biomarkers for differentiating between tubulointerstitial inflammation and interstitial fibrosis/tubular atrophy in kidney allografts. Ann Hepatobiliary Pancreat Surg. 2018;22(4):310–320. doi:10.14701/ahbps.2018.22.4.310
   PubMedGoogle Scholar
• Abdel-Rahman EM, Saadulla L, Reeves WB, Awad AS. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med. 2012;27(4):458–468. doi:10.1007/s11606-011-1912-5
   PubMed Web of Science ®Google Scholar
• Ogawa S, Mori T, Nako K, Ito S. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res. 2008;31(6):1147–1155. doi:10.1291/hypres.31.1147
   PubMed Web of Science ®Google Scholar
• Perlman AS, Chevalier JM, Wilkinson P, et al. Serum inflammatory and immune mediators are elevated in early stage diabetic nephropathy. Ann Clin Lab Sci Spring. 2015;45(3):256–263.
   PubMed Web of Science ®Google Scholar
• Hamid T, Gu Y, Ortines RV, et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation. 2009;119(10):1386–1397. doi:10.1161/CIRCULATIONAHA.108.802918
   PubMed Web of Science ®Google Scholar
• Tamada S, Asai T, Kuwabara N, et al. Molecular mechanisms and therapeutic strategies of chronic renal injury: the role of nuclear factor kappaB activation in the development of renal fibrosis. J Pharmacol Sci. 2006;100(1):17–21. doi:10.1254/jphs.FMJ05003X4
   PubMed Web of Science ®Google Scholar
• Bantel H, Schmitz ML, Raible A, Gregor M, Schulze-Osthoff K. Critical role of NF-kappaB and stress-activated protein kinases in steroid unresponsiveness. FASEB j. 2002;16(13):1832–1834. doi:10.1096/fj.02-0223fje
   PubMed Web of Science ®Google Scholar
• Rayego-Mateos S, Morgado-Pascual JL, Opazo-Ríos L, et al. Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy. Int J Mol Sci. 2020;21(11):3798. doi:10.3390/ijms21113798
   PubMed Web of Science ®Google Scholar
• Yaribeygi H, Butler AE, Barreto GE, Sahebkar A. Antioxidative potential of antidiabetic agents: a possible protective mechanism against vascular complications in diabetic patients. J Cell Physiol. 2019;234(3):2436–2446. doi:10.1002/jcp.27278
   PubMed Web of Science ®Google Scholar
• Lamie PF, Ali WAM, Bazgier V, Rárová L. Novel N-substituted indole Schiff bases as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase enzymes: synthesis, biological activities in vitro and docking study. Eur J Med Chem. 2016;123:803–813. doi:10.1016/j.ejmech.2016.08.013
   PubMed Web of Science ®Google Scholar
• Abdellatif KR, Lamie PF, Omar HA. 3-methyl-2-phenyl-1-substituted-indole derivatives as indomethacin analogs: design, synthesis and biological evaluation as potential anti-inflammatory and analgesic agents. J Enzyme Inhib Med Chem. 2016;31(2):318–324. doi:10.3109/14756366.2015.1022174
   PubMed Web of Science ®Google Scholar
• Rani P, Srivastava VK, Kumar A. Synthesis and antiinflammatory activity of heterocyclic indole derivatives. Eur J Med Chem. 2004;39(5):449–452. doi:10.1016/j.ejmech.2003.11.002
   PubMed Web of Science ®Google Scholar
• Guerra AS, Malta DJ, Laranjeira LP, et al. Anti-inflammatory and antinociceptive activities of indole-imidazolidine derivatives. Int Immunopharmacol. 2011;11(11):1816–1822. doi:10.1016/j.intimp.2011.07.010
   PubMed Web of Science ®Google Scholar
• Amir M, Kumar S. Anti-inflammatory and gastro sparing activity of some new indomethacin derivatives. Arch Pharm. 2005;338(1):24–31. doi:10.1002/ardp.200400891
   PubMed Web of Science ®Google Scholar
• Liu Z, Tang L, Zhu H, et al. Design, synthesis, and structure-activity relationship study of novel indole-2-carboxamide derivatives as anti-inflammatory agents for the treatment of sepsis. J Med Chem. 2016;59(10):4637–4650. doi:10.1021/acs.jmedchem.5b02006
   PubMed Web of Science ®Google Scholar
• Al-Awar A, Kupai K, Veszelka M, et al. Experimental diabetes mellitus in different animal models. J Diabetes Res. 2016;2016:9051426. doi:10.1155/2016/9051426
   PubMedGoogle Scholar
• Ye S, Luo W, Khan ZA, et al. Celastrol attenuates angiotensin ii-induced cardiac remodeling by targeting STAT3. Circ Res. 2020;126(8):1007–1023. doi:10.1161/CIRCRESAHA.119.315861
   PubMed Web of Science ®Google Scholar
• Lee MY, Yuk JE, Kwon OK, Oh SR, Lee HK, Ahn KS. Zuonin B inhibits lipopolysaccharide-induced inflammation via downregulation of the ERK1/2 and JNK pathways in RAW264.7 macrophages. Evid Based Complement Alternat Med. 2012;2012:728196.
   PubMed Web of Science ®Google Scholar
• Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology. 2008;47(4):409–414. doi:10.1093/rheumatology/kem297
   PubMed Web of Science ®Google Scholar
• Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014;124(6):2333–2340. doi:10.1172/JCI72271
   PubMed Web of Science ®Google Scholar
• Wada J, Makino H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol. 2016;12(1):13–26.
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441(7092):431–436. doi:10.1038/nature04870
   PubMed Web of Science ®Google Scholar
• Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes. 2002;51(7):2241–2248. doi:10.2337/diabetes.51.7.2241
   PubMed Web of Science ®Google Scholar
• Chadha N, Silakari O. Indoles as therapeutics of interest in medicinal chemistry: bird’s eye view. Eur J Med Chem. 2017;134:159–184. doi:10.1016/j.ejmech.2017.04.003
   PubMed Web of Science ®Google Scholar
• Kaushik NK, Kaushik N, Attri P, et al. Biomedical importance of indoles. Molecules. 2013;18(6):6620–6662. doi:10.3390/molecules18066620
   PubMed Web of Science ®Google Scholar
• Shattat G, Al-Qirim T, Sheikha GA, et al. The pharmacological effects of novel 5-fluoro-N-(9,10-dihydro-9,10-dioxoanthracen-8-yl)-1H-indole-2-carboxamide derivatives on plasma lipid profile of Triton-WR-1339-induced Wistar rats. J Enzyme Inhib Med Chem. 2013;28(4):863–869. doi:10.3109/14756366.2012.692085
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen L, Yu P, et al. Discovery of 3-(Indol-5-yl)-indazole derivatives as novel myeloid differentiation protein 2/toll-like receptor 4 antagonists for treatment of acute lung injury. J Med Chem. 2019;62(11):5453–5469. doi:10.1021/acs.jmedchem.9b00316
   PubMed Web of Science ®Google Scholar
• Cuarental L, Sucunza-Sáenz D, Valiño-Rivas L, et al. MAP3K kinases and kidney injury. Nefrologia. 2019;39(6):568–580. doi:10.1016/j.nefro.2019.03.004
   PubMed Web of Science ®Google Scholar
• Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 2012;92(2):689–737. doi:10.1152/physrev.00028.2011
   PubMed Web of Science ®Google Scholar
• Yeung YT, Aziz F, Guerrero-Castilla A, Arguelles S. Signaling pathways in inflammation and anti-inflammatory therapies. Curr Pharm Des. 2018;24(14):1449–1484. doi:10.2174/1381612824666180327165604
   PubMed Web of Science ®Google Scholar
• Flyvbjerg A. The role of the complement system in diabetic nephropathy. Nat Rev Nephrol. 2017;13(5):311–318. doi:10.1038/nrneph.2017.31
   PubMed Web of Science ®Google Scholar
• Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S. GLP-1 receptor agonists and kidney protection. Medicina. 2019;55(6):233. doi:10.3390/medicina55060233
   PubMed Web of Science ®Google Scholar